会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • 4-AZOLE SUBSTITUTED IMIDAZOLE COMPOSITIONS USEFUL AS INHIBITORS OR C-MET RECEPTOR TYROSINE KINASE
    • 作为抑制剂或C-MET受体酪氨酸激酶的4-AZO取代的咪唑组合物
    • WO2005040345A3
    • 2005-08-18
    • PCT/US2004031401
    • 2004-09-24
    • VERTEX PHARMAARONOV ALEXLAUFFER DAVID JLI PANTOMLINSON RONALD C
    • ARONOV ALEXLAUFFER DAVID JLI PANTOMLINSON RONALD C
    • A61K31/4178A61K31/4196A61K31/42C07D233/90C07D403/04C07D403/14C07D405/14C07D413/04C07D413/14A61K31/41A61K31/4155A61K31/4184A61K31/422A61P3/08A61P9/00A61P29/00A61P31/12
    • C07D405/14C07D403/04C07D403/12C07D403/14C07D405/12C07D413/04C07D413/12C07D413/14C07D417/04
    • The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders. Formula (I) where Q is C1-6 alkylidene chain wherein one methylene unit of Q is replaced by -C(O)N(R)-, -C(O)-, -C(O)O-, -N(R)-, -O-, -S-, -SO2-, or -SO2N(R)-; each R is independently hydrogen or an optionally substituted C1-6 aliphatic group, wherein: two R groups on the same nitrogen atom are optionally taken together with said nitrogen atom to form an optionally substituted 3-7 membered saturated, partially unsaturated, of fully unsaturated ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R is H, -N(R)2, or an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 5-6 membered aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8-10 membered bicyclic partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R is an optionally substituted 6-membered aryl ring having 0-3 nitrogens; R is R, CN, NO2, halogen, N(R)2, OR, or SR; and Ring A is an optionally substituted ring selected from formulas (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o) or (p).
    • 本发明涉及可用于蛋白激酶抑制剂的化合物。 本发明还提供了制备本发明化合物的方法,包含本发明化合物的药学上可接受的组合物,以及使用该组合物治疗各种疾病的方法。 式(I)其中Q是C 1-6亚烷基链,其中Q的一个亚甲基单元被-C(O)N(R) - , - C(O) - , - C(O) (R) - , - O - , - S - , - SO 2 - 或-SO 2 N(R) - ; 每个R独立地为氢或任选取代的C 1-6脂族基团,其中:相同氮原子上的两个R基团任选与所述氮原子一起形成任选取代的3-7元饱和,部分不饱和的完全不饱和的 具有1-3个独立地选自氮,氧或硫的杂原子的环; R 1是H,-N(R)2或任选取代的环,其选自具有0-3个独立地选自氮,氧或硫的杂原子的3-7元饱和或部分不饱和的环; 具有0-4个独立地选自氮,氧或硫的杂原子的5-6元芳环; 或具有0-4个独立地选自氮,氧或硫的杂原子的8-10元双环部分不饱和或芳环; R 2是具有0-3个氮的任选取代的6元芳环; R 3是R,CN,NO 2,卤素,N(R)2,OR或SR; 环A是选自式(a),(b),(c),(d),(e),(f),(g),(h),(i),(j) ,(k),(l),(m),(n),(o)或(p)。